Press & Statements

CSRxP Letter of Support for Durbin-Grassley DTC Advertising Amendment

Aug 21, 2018

Last night, Senators Durbin and Grassley filed an amendment to the Labor-HHS Read More

CSRxP Statement on CMS Changes to Medicare Part B

Aug 7, 2018

CSRxP spokesman Will Holley released the following statement following Read More

New Report Demonstrates Big Pharma’s Abuses of the Patent System

Aug 2, 2018

CSRxP spokesman Will Holley released the following statement on the release of Read More

High Priced Drugs Lead to Banner Q2 Earnings for Big Pharma

Jul 27, 2018

CSRxP released the following statement following a week of strong Q2 earnings Read More

CSRxP on Lilly & Biogen Earnings

Jul 24, 2018

CSRxP released the following statement following the release of Eli Lilly and Read More

CSRxP Applauds Admin Focus on Drug Prices

Jul 19, 2018

CSRxP spokesman Will Holley released the following statement applauding the Read More

CSRxP Applauds FDA’s Biosimilars Action Plan

Jul 18, 2018

“We applaud Commissioner Gottlieb and the FDA for their leadership on Read More

CSRxP Releases Comments on Drug Price Blueprint

Jul 13, 2018

The Department of Health and Human Services is taking a good first step in the Read More

Statement on Celgene’s Revlimid Price Hike

Jul 10, 2018

CSRxP spokesman Will Holley released the following statement in response to Read More

CSRxP Applauds Secretary Azar’s Focus on List Prices

Jun 26, 2018

CSRxP spokesman Will Holley released the following statement in response to Read More

CSRxP Testimony for the Record: Senate Finance Committee Hearing on Rx Prices

Jun 25, 2018

The Campaign for Sustainable Rx Pricing today released testimony for the Read More

CSRxP Applauds Senate Judiciary Committee for Vote on CREATES Act

Jun 14, 2018

“We applaud the members of the Senate Judiciary Committee for voting the Read More